Advertisement
YOU ARE HERE: LAT HomeCollectionsBabies

Vicks VapoRub may put infants at risk, study finds

The ointment is found to increase mucus production and inflammation, which can exacerbate breathing problems in children under 2, researchers say.

January 13, 2009|Thomas H. Maugh II

Many parents slather Vicks VapoRub on their sniffling, coughing kids when they're sick -- because, by gosh, that's what their parents did to them. For children under the age of 2, the folksy remedy could be dangerous, researchers warned today.

Reporting in Chest, the journal of the American College of Chest Physicians, the researchers said that using the ointment to ease coughing and congestion in children of this age might lead to severe breathing problems by increasing mucus production and inflammation.


Advertisement

The product's label cautions against using Vicks VapoRub on children under 2, but many parents do so anyway, putting their infants at risk, experts said.

"People don't read warnings on prescription medications, so to [read a warning for] a salve on the outside of the body that has been around for 100 years . . . I think it would be a rare parent who would do that," said lead author Dr. Bruce K. Rubin of Wake Forest University Baptist Medical Center in Winston-Salem, N.C.

Vicks VapoRub, whose active ingredients are camphor, menthol and eucalyptus oil, was first formulated in 1891 in Greensboro, N.C. National marketing began in 1905, and it gained great popularity during the Spanish flu epidemic of 1918.

Several small studies have failed to show any medicinal benefit from the ointment, Rubin said. He suspects that the menthol in it binds to cold receptors in the throat, giving the impression that the patient is breathing more easily even when that is not the case.

The ointment's risks came to the attention of Rubin and his colleagues when they treated an otherwise healthy 18-month-old girl who was brought to the emergency room by her grandparents after her respiratory infection suddenly grew worse. Questioning revealed that the severe symptoms appeared shortly after they had put Vicks VapoRub under her nose.

The researchers were already using ferrets -- whose airway anatomy and cell lining are similar to humans -- to study infant respiratory problems. To look at the effect of Vicks, they applied the ointment directly to cultured ferret tracheal cells as well as under the noses of healthy ferrets and ferrets with tracheal inflammation similar to that of humans with a cold.

In the cultured cells, the ointment increased mucus secretion by 59%. It increased secretion by 14% in the airways of healthy animals and by 8% in those with inflamed airways.

Los Angeles Times Articles
|